ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025
Rapid and simple detection of Chlamydia trachomatis and Neisseria gonorrhoeae using the EasyNAT CT/NG assay based on cross-priming amplification.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeChlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) rank among the most common sexually transmitted pathogens. Rapid screening and detection of these bacteria are essential to reduce sequelae and prevent transmission. This study evaluated the efficacy of the EasyNAT CT/NG assay, which utilizes cross-priming amplification (CPA) technique for the rapid and simultaneous detection of CT and NG in diverse reproductive tract specimens, achieving diagnosis within 30 min.
methodsThe clinical performance of the EasyNAT CT/NG assay in detecting CT and NG was assessed using 198 clinical samples, with results compared to those of conventional in-house Real-Time PCR to determine concordance. Sensitivity was measured using serial dilutions of quantified plasmids and specificity was evaluated by incorporating DNA from 18 common STI pathogens. The assay's suitability as a point-of-care testing (POCT) tool was evaluated with the criteria outlined in Target Product Profiles (TPPs).
resultsThe EasyNAT CT/NG assay demonstrated high concordance with Real-Time PCR, with rates of 98.5% for CT and 99.0% for NG. Concordance in urine samples reached 98.6% for CT and 100% for NG, while cervical swabs showed both 97.7% for CT and NG; vaginal and urethral swabs achieved 100% for both pathogens. Among the 198 samples, one urine specimen tested negative for CT by Real-Time PCR but positive by the EasyNAT CT/NG assay, a positive result confirmed by the Cepheid Xpert CT/NG assay. Two cervical swabs, negative for CT and NG by Real-Time PCR, yielded invalid results with the EasyNAT CT/NG assay but were confirmed negative or CT and NG by the Cepheid Xpert CT/NG assay. The EasyNAT CT/NG assay reliably detected CT and NG in turbid specimens, though it may fail with severely hemolytic samples. Its detection limit was 400 copies/mL, with no cross-reactivity observed across 18 other pathogens.
conclusionThe EasyNAT CT/NG assay offers rapid, sensitive, and specific detection of CT and NG, proving valuable for infection screening and early diagnosis. It shows promise as a rapid POCT method.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.